1. Eli Lilly and Company (NYSE:LLY)
Eli Lilly and Company (NYSE: LLY) takes the number-one position because no other company in this ranking currently combines the same level of commercial momentum, pipeline depth and exposure to the rapidly expanding obesity market. Mounjaro and Zepbound have transformed the company’s financial profile, giving it two medicines with the potential to become among the largest pharmaceutical products ever developed. The company also possesses major franchises in oncology, immunology and neuroscience, but metabolic medicine is the engine that has elevated it from a successful traditional drugmaker into one of the world’s most valuable companies.
First-quarter 2026 revenue surged 56% to $19.8 billion, driven primarily by increasing prescription volume for Mounjaro and Zepbound. U.S. Zepbound revenue increased 79% to approximately $4.1 billion, compared with $2.3 billion during the same period in 2025. Growth remained strong even though lower realized prices partially offset the increase in volume. That pricing detail is important because pharmaceutical revenue cannot be evaluated through prescription counts alone. Insurer negotiations, rebates, direct-to-patient programs and product mix all affect the amount manufacturers ultimately collect. Even after those pressures, Eli Lilly and Company (NYSE: LLY) delivered a rate of expansion that the other large pharmaceutical companies on this list could not approach.
The company’s greatest advantage may be that its obesity pipeline extends far beyond its current products. Retatrutide, an experimental medicine targeting GIP, GLP-1 and glucagon receptors, produced an average weight reduction of 28.3% after 80 weeks at the highest dose in the Phase 3 TRIUMPH-1 study. Participants with severe obesity who remained in an extension study achieved average weight loss of 30.3% after 104 weeks. Nearly half of participants receiving the highest dose lost at least 30% of their starting body weight, approaching levels historically associated with bariatric surgery. Additional Phase 3 results released in July 2026 showed average weight loss of 20.8% among patients who also had type 2 diabetes, a population that generally finds it more difficult to lose weight. These results do not guarantee regulatory approval or commercial success, but they suggest that the company may be capable of improving upon medicines that are already generating billions of dollars in revenue.
Eli Lilly and Company (NYSE: LLY) is also developing oral treatments that could expand obesity care beyond patients willing to use injections. Its oral GLP-1 medicine, orforglipron, has completed multiple late-stage studies and is designed to be taken without the food and water restrictions associated with some peptide-based pills. An effective oral medicine could be easier to manufacture, distribute and prescribe across international markets, potentially increasing access while reducing dependence on injectable-device capacity. The company still faces significant risks, including high valuation expectations, pricing pressure, manufacturing demands and aggressive competition from Novo Nordisk A/S (NYSE: NVO) and emerging biotechnology companies. Nevertheless, Eli Lilly and Company (NYSE: LLY) currently possesses the strongest combination of existing blockbuster sales and next-generation pharmaceutical innovation. That makes it the best medicine stock in this ranking and the company every major competitor in obesity and metabolic healthcare is attempting to catch.
YOU MUST READ THIS: 10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
